SCHEMBL488612

SCHEMBL488612

O=c1[nH]c2ncc(Br)cc2o1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 2/20 0.49
DAPK3 O43293 2/20 0.49
JAK2 O60674 2/20 0.49
MAP4K4 O95819 2/20 0.49
PAK4 O96013 2/20 0.49
ABL1 P00519 2/20 0.49
RET P07949 2/20 0.49
FGFR1 P11362 2/20 0.49
PDGFRA P16234 2/20 0.49
FLT1 P17948 2/20 0.49
LTK P29376 2/20 0.49
GRK5 P34947 2/20 0.49
KDR P35968 2/20 0.49
CSNK1A1 P48729 2/20 0.49
CDK8 P49336 2/20 0.49
CLK2 P49760 2/20 0.49
CDK7 P50613 2/20 0.49
CDK9 P50750 2/20 0.49
RPS6KA3 P51812 2/20 0.49
CDK5 Q00535 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13735810 0.79 KDM4E (0.50) AURKADAPK3JAK2MAP4K4PAK4
SCHEMBL24002739 0.79 AURKA (0.46) AURKADAPK3JAK2MAP4K4PAK4
SCHEMBL3865038 0.79 DYRK1A (0.39) AURKADAPK3JAK2MAP4K4PAK4
SCHEMBL30187131 0.79 AURKA (0.46) AURKADAPK3JAK2MAP4K4PAK4
SCHEMBL12232243 0.78 NOS1 (0.49) PDE3BPDE3AKMOGRM5NOS1
SCHEMBL3075895 0.78 NOS1 (0.49) TYRO3LRRK2DYRK1BLMNAMAPT
SCHEMBL3588183 0.78 PDE3B (0.39) JAK2LRRK2LMNAMAPTPDE3B
SCHEMBL17429248 0.74 PDE3B (0.39) AURKADAPK3JAK2MAP4K4PAK4
SCHEMBL28669342 0.74 CREBBP (0.41) LMNAKDM4EALDH1A1MAPTPDE3B
SCHEMBL28522475 0.74 PDE3B (0.36) LMNAPDE3BPDE3AKMONOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111943885-A Synthetic method of Laolatinib intermediate 2-amino-5-bromo-3-hydroxypyridine 西华大学 2020-11-17 CN claimed
WO-2026098560-A2 BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2026-05-15 WO disclosed
US-20260078130-A1 NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF SIRONAX LTD (KY) 2026-03-19 US disclosed
EP-4605089-A1 COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K Mekanistic Therapeutics LLC (US) 2025-08-27 EP disclosed
EP-4590674-A1 NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd (KY) 2025-07-30 EP disclosed
EP-4387965-A2 ARYL SULFONYL COMPOUNDS AS CCR6 INHIBITORS ChemoCentryx, Inc. (US) 2024-06-26 EP disclosed
US-12012403-B2 Aryl sulfonyl compounds as CCR6 inhibitors CHEMOCENTRYX, INC. (US) 2024-06-18 US disclosed
CN-118019735-A Arylsulfonyl compounds as CCR6 inhibitors 坎莫森特里克斯公司 2024-05-10 CN disclosed
WO-2024086296-A1 COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K MEKANISTIC THERAPEUTICS LLC (US) 2024-04-25 WO disclosed
CN-111943885-B Synthesis method of Laratinib intermediate 2-amino-5-bromo-3-hydroxypyridine 西华大学 2023-08-04 CN disclosed
WO-1991006300-A1 NAPHTHERIDINONE- AND PYRIDOOXAZINONE-PYRIDONE COMPOUNDS, CARDIOTONIC COMPOSITIONS INCLUDING SAME, AND THEIR USES RORER INTERNATIONAL (HOLDINGS), INC. (US) 1991-05-16 WO disclosed
EP-0357675-A1 PYRIDOOXAZINONE-PYRIDONE COMPOUNDS, CARDIOTONIC COMPOSITIONS INCLUDING THE SAME, AND THEIR USES RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) 1990-03-14 EP disclosed
US-4866074-A Naphtheridinone- and pyridooxazinone-pyridone compounds, cardiotonic compositions including same, and their uses RORER PHARMACEUTICAL CORPORATION (US) 1989-09-12 US disclosed
US-4822794-A Pyridooxazinone-pyridone compounds, cardiotonic compositions including the same, and their uses RORER PHARMACEUTICAL CORPORATION (US) 1989-04-18 US disclosed
WO-1988008705-A1 PYRIDOOXAZINONE-PYRIDONE COMPOUNDS, CARDIOTONIC COMPOSITIONS INCLUDING THE SAME, AND THEIR USES RORER INTERNATIONAL (OVERSEAS) INC. (US) 1988-11-17 WO disclosed
EP-0063808-B1 PHOTOGRAPHIC ELEMENTS CONTAINING NONDIFFUSIBLE 6-(2-THIENYLAZO)-3-PYRIDINOL CYAN DYE-RELEASING COMPOUNDS EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1985-09-18 EP disclosed
US-4396546-A Photographic products and processes employing novel nondiffusible 6-(2-thienylazo)-3-pyridinol cyan dye-releasing compounds and precursors thereof EASTMAN KODAK COMPANY (US) 1983-08-02 US disclosed
US-4385104-A METAL COORDINATION COMPLEX EASTMAN KODAK COMPANY (US) 1983-05-24 US disclosed
EP-0063808-A1 Photographic elements containing nondiffusible 6-(2-thienylazo)-3-pyridinol cyan dye-releasing compounds EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1982-11-03 EP disclosed
US-4346161-A DIFFUSION TRANSFER EASTMAN KODAK COMPANY (US) 1982-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078130-A1 NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF NAMPT, NNMT, SARM1 AURKA 4522/4885DAPK3 3999/4885JAK2 4382/4885
US-12012403-B2 Aryl sulfonyl compounds as CCR6 inhibitors CCR6, CCR1, CCR3 AURKA 4422/4885DAPK3 2657/4885JAK2 216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.